XML 175 R51.htm IDEA: XBRL DOCUMENT
v3.25.1

Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details) | 3 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Mar. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
Braingenesis Biotechnology Co., Ltd. [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 0.17% | [1] | 0.17% | [1],[2] | 0.17% | [2]
Accounting treatments | Cost Method | [1] | Cost Method | [2] |  |
Genepharm Biotech Corporation [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 0.67% |  | 0.67% |  | 0.67% |
Accounting treatments | Cost Method |  | Cost Method |  |  |
BioHopeKing Corporation [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 5.90% |  | 5.90% |  | 5.90% |
Accounting treatments | Cost Method |  | Cost Method |  |  |
ForSeeCon Eye Corporation [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 19.78% |  | 19.78% |  |  |
Accounting treatments | Cost Method |  | Cost Method |  |  |
BioFirst Corporation [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 18.68% |  | 18.68% |  | 18.68% |
Accounting treatments | Equity Method |  | Equity Method |  |  |
OncoX BioPharma, Inc. [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 24.97% |  | 24.97% |  |  |
Accounting treatments | Equity Method |  | Equity Method |  |  |
Rgene Corporation [Member] |  |  |  |  |  |
Schedule of Ownership Percentages of Each Investee [Line Items] |  |  |  |  |  |
Ownership percentage | 37.00% |  | 26.65% |  | 26.65% |
Accounting treatments | Equity Method |  | Equity Method |  |  |
[1] | This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.
[2] | This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.

X
- Definition This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership. + References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentAdditionalInformation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_ForSeeConEyeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_BioFirstCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_OncoXBioPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |